Abstract
A small implantable centrifugal left ventricular assist device, the CH-VAD (CH Biomedical Inc, JiangSu, China), featuring a magnetically levitated impeller is under development. The goal of this study is to validate hydrodynamic performance and hemocompatibility of the pump through in vitro studies. The hydraulic performance was quantified experimentally by using in vitro circulation loop system, and it turned out that the pump could deliver 5[Formula: see text]L/min under a pressure of 100[Formula: see text]mmHg at a rotational speed of approximate 3400[Formula: see text]rpm. A series of in vitro tests were established according to ASTM F1841, the standard practice for the assessment of hemolysis in continuous-flow blood pumps. The results showed that the average normalized index of hemolysis (NIH) value of the VAD was 0.0007[Formula: see text][Formula: see text][Formula: see text]0.0003[Formula: see text]mg/dL. The magnetic levitation left ventricular assist device (LVAD) has good hemolytic performance and stable mechanical property. These acceptable performance results supported proceeding initial acute animal testing conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
